Business Model

MAB Discovery intends to engage in collaborations with partners using its robust platform to discover, isolate and characterize monoclonals of unprecedented quality in terms of potency, functionality and epitope coverage.

MAB Discovery can go all the way from immunization to delivery of well-characterized cell lines producing clinical candidates. Hand off of intermediates at any stage is also possible.

MAB Discovery is offering flexible and straightforward business terms: technology access fees , research support, success milestones, royalties, and no gate-keeping.

For more information please contact: